Donate Tissue

Tag: COLLABORATION

  • Cell2Cure is partner in an EU-funded project, RESTORE VISION, within rare eye diseases

    Cell2Cure is partner in an EU-funded project, RESTORE VISION, within rare eye diseases

    In Europe, approximately 30 million people suffer from blindness and visual impairment. Rare Eye Diseases are a major cause that can result in blindness in children and young adults and affect adults and the ageing population. Current management is expensive, has low efficacy, and significant side effects.

    The consortium – RESTORE VISION – aims to address this clinical need by formulating novel treatments and repurposed drugs that have been validated in different disease indications (Home – Restore vision).

    The project will target seven rare eye diseases: aniridia-associated keratopathy; neurotrophic keratopathy; limbal stem cell deficiency; ocular cicatricial pemphigoid; EEC syndrome; ocular graft versus host disease; and corneal neovascularisation.

    Cell2Cure participate in the consortium with the patented cell product: allogeneic adipose tissue-derived mesenchymal stromal/stem cells (ASCs) and our expertise within conduction of clinical trials.

    The ASC products will be tested in a clinical trial as an immunosuppressive treatment in patients with ocular graft versus host disease.

  • Cell2Cure enters a collaboration agreement with Endeavour Cells ApS

    Cell2Cure enters a collaboration agreement with Endeavour Cells ApS

    Cell2Cure has entered a collaboration agreement with Endeavour Cells ApS, to collaborate on the preparation, conduct, management, and completion of an un-blinded phase I/II clinical trial in children with autism.

    The clinical trial title is “Effect of adipose derived mesenchymal stromal cells on autism and leaky gut syndrome”.

    Endeavour Cells will financially sponsor the trial, but Cell2Cure will have the role as clinical sponsor.

    It is expected that the trial will be ready to enroll the first participant early 2023.

  • Cell2Cure enters a sublicense agreement with Endeavour Cells ApS

    Cell2Cure enters a sublicense agreement with Endeavour Cells ApS

    Cell2Cure has entered a sublicense agreement with Endeavour Cells ApS, which will allow Endeavour Cells ApS to develop, manufacture and commercialize allogeneic adipose tissue-derived mesenchymal stromal/stem cells (ASCs) for the treatment of Autism Spectrum Disorder (ASD), Attention Deficit Hyperactivity Disorder (ADHD), Attention Deficit Disorder (ADD), and other heterogeneous neurodevelopmental disorders with or without gastrointestinal issues.

    The agreements include down- and milestone payments, and ongoing service, support, and management of the project on undisclosed commercial terms.

  • Collaboration agreement between Cell2Cure and Cbio A/S

    Collaboration agreement between Cell2Cure and Cbio A/S

    Cell2Cure has entered a collaboration agreement with Cbio A/S to establish Cell2Cure’s own GMP facility for production of adipose tissue-derived mesenchymal stromal/stem cell products (ASCs) in Cbio’s newly established and approved cell production facility, Transformervej 8, 2860 Søborg, Denmark.

    Cell2cure has a license from Rigshospitalet, Copenhagen, to a proprietary ASC production technology platform.

    C2C will in these new facilities further develop ASC product portfolio and continue clinical development programs for diseases with inflammatory, immunological and tissue/function re-generation components involved.

  • Cell2Cure partner in a new Stem Cell Center

    Cell2Cure partner in a new Stem Cell Center

    Cell2Cure, as part of the consortium Clinical Stem cell Innovation and production Center (CSIC), receives funding from Innovation Fund Denmark. CSIC embraces late-stage development of ASCs – with an aim to mature process knowledge and product quality as a prerequisite for production up-scale; expand product portfolio and down-stream processing, improve the scientific rationale and complete a clinical dose titrating trial in 30 patients having a lung transplantation, while identifying a feasible regulatory strategy addressing safety, quality and efficacy.

    In short, the Center prepares stem cell therapy for pivotal trials, investments, and final market access, bringing stem cells the last important steps to the market and to actually being used by health care systems, for the benefit of patients worldwide. Consortium partners are University Hospital Copenhagen, Sexton Biotechnologies, University of Copenhagen and Cell2Cure and received 25 million DKK in funding.